The soluble guanylate cyclase stimulator named vericiguat as an innovative heart failure therapy representative
A noticeable trend towards greater heart failure morbidity is observed in Poland as well as in the whole world. The percentage of people living with the above mentioned disease is growing mostly due to the process of ageing of populations. As per the epidemiological data from 2017 report 70 million...
Saved in:
Main Authors: | Beata Jacuś (Author), Mirosława Kowalkowska (Author), Paweł Miękus (Author), Grzegorz Grześk (Author) |
---|---|
Format: | Book |
Published: |
Polish Pharmaceutical Society,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy
by: Bo-ang Hu, et al.
Published: (2023) -
Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice.
by: Beata Jacuś, et al.
Published: (2021) -
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
by: Lian TY, et al.
Published: (2017) -
Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress
by: Melissa H Costell, et al.
Published: (2012) -
Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020)